BIOFILCHEM.NS (Biofil Chemicals) falls 18.99% to INR 37.54 on 05 Feb 2026 (NSE): watch liquidity and support near INR 28.50

BIOFILCHEM.NS stock closed as a top loser on 05 Feb 2026 after plunging 18.99% to INR 37.54 on the NSE. Volume jumped to 115,236 shares versus an average of 38,098, signalling one-sided selling into the close. Intraday high was INR 40.37 and the stock opened at INR 40.37 after a previous close of INR 46.34. We view the drop as a liquidity-driven move layered on valuation worries and stretched receivables; Meyka AI’s analysis flags near-term downside to model support levels and elevated volatility for traders and investors.

BIOFILCHEM.NS stock: intraday drivers and volume spike

The immediate driver for BIOFILCHEM.NS stock’s decline was heavy selling with relative volume 9.14, pushing price to the day low of INR 37.54. One-day change was -8.80 INR or -18.99%, with average 50-day price at INR 33.61 and 200-day average at INR 41.37.

The trade showed concentration: 115,236 shares traded against an average of 38,098, suggesting institutional or block selling rather than retail drip. With on-balance volume negative and RSI at 38.66, momentum is bearish but not yet capitulative.

Valuation and fundamentals driving the selloff

Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.NS) trades at a P/E near 23.83 with EPS INR 1.75 and market cap INR 678,780,198. Price-to-book is 3.27 and price-to-sales is 1.60, above many small-cap peers in the drug manufacturers segment.

Key red flag: days sales outstanding 350.00 days and receivables turnover 1.04, which point to working capital strain. Current ratio 1.44 and near-zero debt reduce solvency worries, but slow collections amplify liquidity risk and likely influenced the selloff.

Technical setup, supports and resistance

Technically, the stock breached near-term support at the 50-day mean and sits below the 200-day average INR 41.37. Short-term indicators show RSI 38.66, CCI -127.96 and ADX 32.41 indicating a strong downtrend.

Immediate support is the year low INR 28.50 and a short-term floor near INR 29.00. Resistance lies at INR 41.37 (200-day MA) and then the previous close INR 46.34. Traders should watch volume to confirm any reversal.

Meyka AI rates BIOFILCHEM.NS with a score out of 100

Meyka AI rates BIOFILCHEM.NS with a score out of 100: 62.79 (Grade B) – HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

The grade reflects mixed fundamentals: strong asset coverage and low leverage but weak cash conversion and stretched receivables. This is informational and not financial advice.

Meyka AI’s forecast and price targets

Meyka AI’s forecast model projects monthly INR 29.29, quarterly INR 20.98, and yearly INR 18.58. Compared with the current price INR 37.54, implied moves are -21.98% (monthly), -44.15% (quarterly) and -50.49% (yearly). Forecasts are model-based projections and not guarantees.

We set pragmatic targets: near-term support INR 28.50, conservative recovery target INR 45.00 if fundamentals improve, and bear-case technical target aligned with the quarterly forecast INR 20.98. No consensus price target is available from brokers.

Risks and what investors should watch next

Primary risks include slower receivables collection, margin pressure from commodity inputs, and continued low free cash flow. With days sales outstanding at 350.00 days, any operational slowdown could push working capital needs higher.

Watch for quarterly earnings updates, changes to receivables disclosure, and any management commentary on job-work volumes. Also monitor sector flows: Healthcare peers show muted performance, which may limit a sector-led recovery.

Final Thoughts

BIOFILCHEM.NS stock closed as a top loser on 05 Feb 2026 after an 18.99% selloff to INR 37.54, driven by a sharp volume spike and renewed focus on stretched receivables. Fundamentals are mixed: low leverage and positive ROE contrast with a very long DSO (350.00 days) and weak cash conversion. Meyka AI’s grade (B, 62.79) signals a HOLD stance — not a buy signal — reflecting both balance-sheet strengths and operational risks. Meyka AI’s forecast model projects monthly INR 29.29 (implied -21.98%), quarterly INR 20.98 (-44.15%), and yearly INR 18.58 (-50.49%) versus the current price INR 37.54; these are model outputs, not guarantees. For investors, the actionable checklist is clear: confirm receivables improvement, watch volume for conviction, and use INR 28.50 as hard support. Short-term traders should treat the move as high-risk, while longer-term holders should await clearer signs of improved cash conversion before increasing exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.